Anti-VEGF TKIs (sorafenib, axitinib, or pazopanib) are used in the treatment of kidney cancer advanced renal cell carcinoma (RCC), or hepatocellular carcinoma (HCC). This evidence concerns the gene VEGFA and renal cell carcinoma.